Cancer immunotherapy has seen significant progress with immune checkpoint blockade and chimeric antigen receptor (CAR) T cell therapies. These breakthroughs highlight the importance of understanding tumor immunology for effective clinical treatment. This review series discusses recent developments in cancer immunology and immunotherapy, focusing on immune checkpoint and CAR T cell therapies, which mark a new era in cancer treatment. The immune system can recognize and eliminate cancer cells, but tumors evade detection by creating an immunosuppressive environment. Tumor cells avoid immune recognition through mechanisms such as downmodulating antigen presentation, recruiting suppressor cells, and producing immunosuppressive factors. Understanding these mechanisms is crucial for developing new immunotherapies. Immune checkpoint blockade, which inhibits CTLA-4 and PD-1, has shown promise in treating cancers like melanoma. PD-1 blockade has also been successful in treating various solid tumors. CAR T cell therapy involves modifying T cells to target cancer cells, showing efficacy in treating B-cell malignancies. Therapeutic cancer vaccines and tumor neoantigens are also being explored. Neoantigens, derived from tumor-specific mutations, are promising targets for immunotherapy. Advances in next-generation sequencing and epitope prediction are improving the identification of neoantigens for personalized treatment. Despite these advances, immunotherapy is not effective in all cancers, and further research is needed to improve outcomes. Understanding the immunosuppressive tumor microenvironment and the role of neoantigens is essential for developing more effective therapies. Continued research in tumor immunology will lead to better treatments for cancer patients.Cancer immunotherapy has seen significant progress with immune checkpoint blockade and chimeric antigen receptor (CAR) T cell therapies. These breakthroughs highlight the importance of understanding tumor immunology for effective clinical treatment. This review series discusses recent developments in cancer immunology and immunotherapy, focusing on immune checkpoint and CAR T cell therapies, which mark a new era in cancer treatment. The immune system can recognize and eliminate cancer cells, but tumors evade detection by creating an immunosuppressive environment. Tumor cells avoid immune recognition through mechanisms such as downmodulating antigen presentation, recruiting suppressor cells, and producing immunosuppressive factors. Understanding these mechanisms is crucial for developing new immunotherapies. Immune checkpoint blockade, which inhibits CTLA-4 and PD-1, has shown promise in treating cancers like melanoma. PD-1 blockade has also been successful in treating various solid tumors. CAR T cell therapy involves modifying T cells to target cancer cells, showing efficacy in treating B-cell malignancies. Therapeutic cancer vaccines and tumor neoantigens are also being explored. Neoantigens, derived from tumor-specific mutations, are promising targets for immunotherapy. Advances in next-generation sequencing and epitope prediction are improving the identification of neoantigens for personalized treatment. Despite these advances, immunotherapy is not effective in all cancers, and further research is needed to improve outcomes. Understanding the immunosuppressive tumor microenvironment and the role of neoantigens is essential for developing more effective therapies. Continued research in tumor immunology will lead to better treatments for cancer patients.